20131217_4

ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.

April 26, 2024

Vol.50 No.17

By Jacquelyn Cobb

Conversation with The Cancer Letter

Clearing the path for MRD as early endpoint in multiple myeloma

Sylvester’s C. Ola Landgren: “I was convinced that this is really the way to go”

Black patients with multiple myeloma aren’t getting autoHCT as often as others—and the disparity has widened

Black patients are less likely than patients of other races and ethnicities to receive autologous hematopoietic cell transplants for multiple myeloma, according to a study published in the April issue of Clinical Lymphoma, Myeloma, and Leukemia.

April 26, 2024

Vol.50 No.17

By McKenzie Prillaman

Conversation with The Cancer Letter

ARPA-H’s Andrew Carney: Join the AI Cyber Challenge to counter cyberattacks on health systems

Can AI-enabled technology safeguard hospitals, pharmacies, and medical devices from cyberattacks?

April 26, 2024

Vol.50 No.17

By Matthew Bin Han Ong

In the Archives

Paul Grotzinger and Jerry Hanks: Fox Chase pioneers

Fox Chase Cancer Center has contributed two articles to the Cancer History Project, documenting the impact of Paul Grotzinger and Gerald “Jerry” Hanks.

April 26, 2024

Vol.50 No.17

In Brief

RUSH becomes seventh partner in MD Anderson network

MD Anderson Cancer Center and RUSH University System for Health are collaborating to create RUSH MD Anderson Cancer Center.

April 26, 2024

Vol.50 No.17

YOU MAY BE INTERESTED IN

ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma

Clearing the path for MRD as early endpoint in multiple myeloma

Black patients with multiple myeloma aren’t getting autoHCT as often as others—and the disparity has widened

ARPA-H’s Andrew Carney: Join the AI Cyber Challenge to counter cyberattacks on health systems

Paul Grotzinger and Jerry Hanks: Fox Chase pioneers

RUSH becomes seventh partner in MD Anderson network

Renew today!

Subscriber content

Login

	Why I Don’t Want to Pay for Your Horoscope:Reflections on FDA Warning to 23andMeGuest Editorial by Jim EvansThere’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic profiling. And adding to 23andMe’s woes, a class action suit has been filed against them.
	Bipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023By Matthew Bin Han OngThe House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023.
	In Brief Thomas Burke stepped down as executive vice president and physician-in-chief at MD Anderson Cancer Center Edward Jackson named chair of the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health David Chang appointed professor of plastic surgery at the University of Chicago School of Medicine Steve Mackin named chief operating officer of Cancer Treatment Centers of America